Proto-Oncogene Proteins B-raf
-
Subject Areas on Research
- A Multivariate Computational Method to Analyze High-Content RNAi Screening Data.
- A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
- Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).
- BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.
- BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases.
- BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
- BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation.
- Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms.
- Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?
- Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles.
- Colon cancer, version 3.2014.
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
- Copper is required for oncogenic BRAF signalling and tumorigenesis.
- Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas.
- Elution profile analysis of SDS-induced subcomplexes by quantitative mass spectrometry.
- Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades.
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
- Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
- Histological and molecular evaluation of patient-derived colorectal cancer explants.
- Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.
- LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
- Melanoma brain metastasis: overview of current management and emerging targeted therapies.
- Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
- Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis.
- Mutations of the BRAF gene in human cancer.
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
- Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma.
- Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.
- Papillary thyroid cancer.
- Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct.
- Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
- Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
- Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.
- The molecular diagnosis and management of thyroid neoplasms.
-
Keywords of People
- Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
- McCall, Shannon Jones, Associate Professor of Pathology, Pathology
- Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics